CH668188A5 - Corticosteroid ointment compsns. - comprise e.g. dexamethasone in poly:alkylene glycol base, and are used esp. for treating rhinitis - Google Patents

Corticosteroid ointment compsns. - comprise e.g. dexamethasone in poly:alkylene glycol base, and are used esp. for treating rhinitis Download PDF

Info

Publication number
CH668188A5
CH668188A5 CH231686A CH231686A CH668188A5 CH 668188 A5 CH668188 A5 CH 668188A5 CH 231686 A CH231686 A CH 231686A CH 231686 A CH231686 A CH 231686A CH 668188 A5 CH668188 A5 CH 668188A5
Authority
CH
Switzerland
Prior art keywords
ointment
polyethylene glycol
agent
ointment base
nasal
Prior art date
Application number
CH231686A
Other languages
German (de)
Inventor
Franz Rappai
Original Assignee
Franz Rappai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Franz Rappai filed Critical Franz Rappai
Priority to CH231686A priority Critical patent/CH668188A5/en
Publication of CH668188A5 publication Critical patent/CH668188A5/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Abstract

Ointment compsns., esp. for treating allergic and vasomotor rhinitis, contain (a) at least one steroid (I) of the 16-methyl-1,4-pregnadiene-3,20-dione series and (b) an ointment base comprising mainly a physiologically acceptable component (II) which is liq. or semi-liq. at body temp. and is capable of reducing surface tension. (I) is pref. dexamethasone (Ia) or its derivs., e.g. the t-butyl acetate, or beclomethasone (Ib) or its derivs., e.g. the 21-acetate or dipropionate. (II) is a polyalkylene glycol, esp. a polyethylene glycol (PEG) mixt., opt. mixed with a higher fatty alcohol. The compsns. may also contain preservatives and/or NaCl. ADVANTAGE - Unlike conventional nasal sprays, the ointments do not cause drying of the nasal mucosa.

Description

       

  
 

**WARNUNG** Anfang DESC Feld konnte Ende CLMS uberlappen **.

 



      PATENTANSPRÜCHE   
1. Mittel in Salbenform, insbesondere zur Behandlung von allergischen und vasomotorischen Rhinitiden, dadurch gekennzeichnet, dass es mindestens eine Steroidverbindung der 16-Methylpregna-1,4-dien-3,20-dion-Reihe und eine Salbengrundlage, welche zur Hauptsache aus einer bei Körpertemperatur flüssigen oder halbflüssigen, die Oberflächenspannung herabsetzenden, physiologisch annehmbaren Komponente besteht, enthält.



   2. Mittel nach Patentanspruch 1, dadurch gekennzeichnet, dass die Salbengrundlage zur Hauptsache aus Polyalkylenglykolen besteht.



   3. Mittel nach Patentanspruch 1 oder 2, dadurch gekennzeichnet, dass die Polyalkylenglykole aus einem Gemisch von Polyäthylenglykolen von verschiedenem Molekulargewicht bestehen.



   4. Mittel nach einem der Patentansprüche 1 bis 3, dadurch gekennzeichnet, dass die Salbengrundlage ausserdem mindestens einen höheren Fettalkohol wie z.B. Cetylalkohol und/oder Stearylalkohol enthält.



   5. Mittel nach einem der Patentansprüche 1 bis 4, dadurch gekennzeichnet, dass es ausserdem ein Konservierungsmittel enthält, z.B. ein Salz- oder einen Ester der Benzoesäure.



   6. Mittel nach einem der Patentansprüche 1 bis 5, dadurch gekennzeichnet, dass es ausserdem Natriumchlorid, vorzugsweise in Form von Meersalz, enthält.



   7. Mittel nach einem der Patentansprüche 1 bis 6, dadurch gekennzeichnet, dass es als Wirkstoff 9-Fluor   1113, 17,21-trihydroxy-16z-methylpregna- 1 ,4-dien-3,20-dion    oder einen Ester davon, z.B. das tert.-Butylacetat, enthält.



   8. Mittel nach einem der Patentansprüche 1 bis 6, dadurch gekennzeichnet, dass es als Wirkstoff 9-Chlor   -11      1      7,21-trihydroxy- 1 613-methylpregna-l    ,4-dien-3,20-dion oder dessen Ester, z.B. das 21-Acetat oder das Dipropionat, enthält.



   BESCHREIBUNG



   Die Erfindung betrifft ein Mittel in Salbenform, insbesondere zur Behandlung von allergischen und vasomotorischen Rhinitiden, dessen wesentliche Bestandteile ein oder mehrere Wirkstoffe der 16-Methylpregna-1,4-dien-3,20dion-Reihe sowie eine Salbengrundlage auf der Basis von bei Körpertemperatur flüssigen oder   halbflüssigen,    die Oberflächenspannung herabsetzenden Verbindungen sind.



   Die als Wirkstoffe verwendeten Corticosteroide üben eine ausgezeichnete antiallergische Wirkung auf die Nasenschleimhäute aus. Bisher wurden sie zu diesem Zweck als Nasensprays eingesetzt, wobei sie aber eine sehr unangenehme und unerwünschte Austrocknung der Schleimhäute hervorriefen.



   Aufgabe der Erfindung war es daher, ein Mittel zu entwickeln, welches die positiven Wirkungen der Corticosteroide ohne das Austrocknen der Nasenschleimhäute erzielt.



   Das erfindungsgemässe Mittel ist in Patentanspruch 1 definiert.



   Das erfindungsgemässe Mittel bekämpft mit Hilfe der Corticosteroide insbesondere die unten genannten Krankheitssymptome. Durch die spezielle Salbengrundlage bleibt die Wirkung der Corticosteroide voll erhalten und gleichzeitig bleiben überraschenderweise die Schleimhäute während der Entfaltung der Wirkung feucht. Die austrocknende Nebenwirkung der Corticosteroide wird durch die   befeuchtende    Wirkung der Salbengrundlage aufgehoben. Dadurch bleiben die physiologischen Zustände der Schleimhäute erhalten, was mit wässerigen Präparaten nicht immer der Fall ist.



   Als Hauptbestandteil der Salbengrundlage dient eine bei Körpertemperatur flüssige oder halbflüssige die Oberflächenspannung herabsetzende Komponenente, die selbstverständlich physiologisch annehmbar sein muss. Verbindungen dieser Art, die allein oder im Gemisch verwendet werden können, sind z. B. Polyalkylenglykole, insbesondere Poly äthylenglykole. Eine besonders bevorzugte Komponente besteht aus einem Gemisch von Polyäthylenglykolen von verschiedenem Molekulargewicht, z.B. Polyäthylenglykol 600, Polyäthylenglykol 1000, Polyäthylenglykol 2000, Polyäthylenglykol 3000 und Polyäthylenglykol 5000, die in verschiedenen Gemischen von zwei oder mehr Komponenten und in verschiedenen Mengenverhältnissen miteinander vermischt werden können.



   Es hat sich ferner als vorteilhaft erwiesen, der Salbe weitere, für Nasensalben bekannte Zusätze beizufügen, z.B.



  Verbindungen mit einer gewissen Schmierwirkung, wie höhere Fettalkohole; Kochsalz, insbesondere in Form von Meersalz, sowie Konservierungsmittel, z. B. Benzoesäuresalze oder -ester.



   Als Wirkstoffe eignen sich bekannte Verbindungen der   16-Methyl-pregna-1,4-dien-3,20-dion-Reihe    wie Dexamethason und Beclomethason und deren Derivate, insbesondere deren Ester.



   Geeignete Wirkstoffkonzentrationen liegen im allgemeinen bei etwa   0,1 - 2    Gew.%.



   Patienten, welche auf Pollen oder andere Substanzen allergisch reagieren, leiden jährlich und in ständig steigendem Masse an den Folgen dieser Allergien mit Nasentropfen, tränenden und geschwollenen Augen, etc. In extremen Fällen sind diese Patienten so stark behindert, dass Arbeitsunfähigkeit auftritt. Viele dieser Patienten werden mit Medikamenten behandelt, die als unerwünschte Nebenwirkung die Schleimhäute austrocknen lassen. Dies wird durch das erfindungsgemässe Mittel verhindert. Eine weitere Patientengruppe leidet an vasomotorischen Rhinitiden, deren Symptome den allergischen Rhinitiden ähnelt.



   Es besteht daher auch hier die Notwendigkeit, diese unangenehmen Symptome mit einem geeigneten Mittel zu behandeln, dessen Nebenwirkungen auf ein Minimum reduziert sind, was mit dem erfindungsgemässen Mittel auf einfache Weise ermöglicht wird. Durch die spezielle Salbengrundlage,   z.B.    auf Polyalkylenglykol-Basis, werden die Nebenwirkungen der Wirkstoffe aufgehoben und eine optimale Behandlung ist gewährleistet.



   Mit Hilfe dieses erfindungsgemässen Mittels wird die Austrocknung der Nasenschleimhäute erfolgreich verhindert und Erkrankungen, wie z. B. Rhinitis allergica und vasomotorica, können innert kurzer Zeit erfolgreich behandelt werden, so dass nach wenigen Minuten schon subjektiv und objektiv eine wesentliche Besserung des Zustandes des Patienten festgestellt werden kann.



   Nachstehend wird die Erfindung durch zwei Beispiele näher erläutert.



   Beispiel 1
Aus den folgenden Bestandteilen wurde auf übliche Weise eine Nasensalbe hergestellt: Polyäthylenglykol 600 40 g Polyäthylenglykol 2000 20 g Cetylalkohol 10 g Sorbitol   5g      Meersalz (NaCl    + Spurenelemente) 1,3 g Methylparabenzoat 0,1 g   Wasser 22,6 g Dexamethason (9-Fluoro-   1113,17,21 -tri-    hydroxy- 1 6a-methylpregna- 1   ,4-dien-    3,20-dion) oder dessen Derivate, wie z. B.

  Dexamethason-tert.-butylacetat, etc. 1 g
100 g
Beispiel 2
Die folgenden Bestandteile wurden zu einer Nasensalbe verarbeitet: Wasser 25,2 g Polyäthylenglykol 600 30 g Polyäthylenglykol 1000 10 g Polyäthylenglykol 3000 10 g Polyäthylenglykol 5000   10    g Stearylalkohol 10 g Meersalz (NaCl   +    Spurenelemente) 0,6 g Sorbitol   4g      Beclomethason (9-Chlor-l Iss,17,21-tri- hydroxy- 1 6ss-methylpregna- 1 ,4-dien-      3;20-dion)    oder dessen Derivate, wie z.B. Beclomethason-21-acetat und Beclomethason-dipropionat 0,2 g
100 g
Zur Anwendung des erfindungsgemässen Mittels wird es in geeigneten Zeitabständen auf die Nasenschleimhäute aufgetragen. 

  Zur Erzielung des gewünschten Effektes werden im allgemeinen Salbenmengen aufgetragen, die 10 bis 1000 mg Reinwirkstoff pro Applikation entsprechen.



   Zur Applikation der Salbe geeignete Vorrichtungen, die auf dem Markt erhältlich sind, sind verlängerte Tubenkanülen oder Tubenöffnungen, die in die Nasenöffnungen eingeführt werden. Das Mittel kann gegebenenfalls auch mit dem Finger oder einem Wattestäbchen auf die Nasenschleimhäute appliziert werden. Die Anwendung kann bei Bedarf mehrmals und über längere Zeit wiederholt werden, ohne dass unerwünschte Nebenwirkungen auftreten, wie klinische Versuche an Menschen gezeigt haben. 



  
 

** WARNING ** beginning of DESC field could overlap end of CLMS **.

 



      PATENT CLAIMS
1. Agent in ointment form, in particular for the treatment of allergic and vasomotor rhinitis, characterized in that there is at least one steroid compound of the 16-methylpregna-1,4-diene-3,20-dione series and an ointment base, which mainly consists of a contains at body temperature liquid or semi-liquid, the surface tension-reducing, physiologically acceptable component.



   2. Composition according to claim 1, characterized in that the ointment base consists mainly of polyalkylene glycols.



   3. Composition according to claim 1 or 2, characterized in that the polyalkylene glycols consist of a mixture of polyethylene glycols of different molecular weights.



   4. Agent according to one of claims 1 to 3, characterized in that the ointment base is also at least one higher fatty alcohol such as Contains cetyl alcohol and / or stearyl alcohol.



   5. Agent according to one of claims 1 to 4, characterized in that it also contains a preservative, e.g. a salt or an ester of benzoic acid.



   6. Composition according to one of claims 1 to 5, characterized in that it also contains sodium chloride, preferably in the form of sea salt.



   7. Composition according to one of the claims 1 to 6, characterized in that it contains 9-fluorine 1113, 17,21-trihydroxy-16z-methylpregna-1,4-diene-3,20-dione or an ester thereof, e.g. contains the tert-butyl acetate.



   8. Composition according to one of the claims 1 to 6, characterized in that it contains 9-chloro -11 1 7,21-trihydroxy-1,613-methylpregna-l, 4-diene-3,20-dione or its ester as active ingredient, e.g. 21-acetate or dipropionate.



   DESCRIPTION



   The invention relates to an agent in ointment form, in particular for the treatment of allergic and vasomotor rhinitis, the essential components of which are one or more active ingredients of the 16-methylpregna-1,4-diene-3,20dione series and an ointment base on the basis of those which are liquid at body temperature or semi-fluid compounds that reduce surface tension.



   The corticosteroids used as active substances have an excellent anti-allergic effect on the nasal mucosa. So far, they have been used for this purpose as nasal sprays, but they have caused a very unpleasant and undesirable drying of the mucous membranes.



   The object of the invention was therefore to develop an agent which achieves the positive effects of corticosteroids without drying out the nasal mucous membranes.



   The agent according to the invention is defined in claim 1.



   With the help of corticosteroids, the agent according to the invention in particular combats the disease symptoms mentioned below. Due to the special ointment base, the effect of the corticosteroids is fully preserved and, at the same time, surprisingly the mucous membranes remain moist during the development of the effect. The drying side effect of the corticosteroids is eliminated by the moisturizing effect of the ointment base. As a result, the physiological conditions of the mucous membranes are preserved, which is not always the case with aqueous preparations.



   The main component of the ointment base is a component which is liquid or semi-liquid at body temperature and which reduces the surface tension, which of course must be physiologically acceptable. Compounds of this type, which can be used alone or in a mixture, are e.g. B. polyalkylene glycols, especially poly ethylene glycols. A particularly preferred component consists of a mixture of polyethylene glycols of different molecular weights, e.g. Polyethylene glycol 600, polyethylene glycol 1000, polyethylene glycol 2000, polyethylene glycol 3000 and polyethylene glycol 5000, which can be mixed in different mixtures of two or more components and in different proportions.



   It has also proven advantageous to add further additives known to nasal ointments to the ointment, e.g.



  Compounds with a certain lubricating effect, such as higher fatty alcohols; Cooking salt, especially in the form of sea salt, and preservatives, e.g. B. benzoic acid salts or esters.



   Known compounds of the 16-methyl-pregna-1,4-diene-3,20-dione series, such as dexamethasone and beclomethasone and their derivatives, in particular their esters, are suitable as active ingredients.



   Suitable drug concentrations are generally around 0.1-2% by weight.



   Patients who are allergic to pollen or other substances suffer annually and to an ever increasing extent from the consequences of these allergies with nose drops, watery and swollen eyes, etc. In extreme cases, these patients are so severely handicapped that they are unable to work. Many of these patients are treated with medications that cause the mucous membranes to dry out as an undesirable side effect. This is prevented by the agent according to the invention. Another group of patients suffers from vasomotor rhinitis, the symptoms of which are similar to allergic rhinitis.



   There is therefore also a need to treat these unpleasant symptoms with a suitable agent, the side effects of which are reduced to a minimum, which is made possible in a simple manner with the agent according to the invention. Due to the special ointment base, e.g. based on polyalkylene glycol, the side effects of the active ingredients are eliminated and optimal treatment is guaranteed.



   With the help of this agent the drying of the nasal mucous membranes is successfully prevented and diseases such as. B. Rhinitis allergica and vasomotorica, can be treated successfully within a short time, so that after a few minutes, a substantial improvement in the patient's condition can be determined subjectively and objectively.



   The invention is explained in more detail below by means of two examples.



   example 1
A nasal ointment was prepared in the usual way from the following constituents: polyethylene glycol 600 40 g polyethylene glycol 2000 20 g cetyl alcohol 10 g sorbitol 5 g sea salt (NaCl + trace elements) 1.3 g methyl parabenzoate 0.1 g water 22.6 g dexamethasone (9-fluoro - 1113,17,21 -tri- hydroxy- 1 6a-methylpregna- 1, 4-diene-3.20-dione) or its derivatives, such as. B.

  Dexamethasone tert-butyl acetate, etc. 1 g
100 g
Example 2
The following ingredients were processed into a nasal ointment: water 25.2 g polyethylene glycol 600 30 g polyethylene glycol 1000 10 g polyethylene glycol 3000 10 g polyethylene glycol 5000 10 g stearyl alcohol 10 g sea salt (NaCl + trace elements) 0.6 g sorbitol 4 g beclomethasone (9-chlorine -l Iss, 17,21-tri-hydroxy-1 6ss-methylpregna-1, 4-diene-3; 20-dione) or its derivatives, such as Beclomethasone 21-acetate and beclomethasone dipropionate 0.2 g
100 g
To use the agent according to the invention, it is applied to the nasal mucosa at suitable intervals.

  To achieve the desired effect, amounts of ointment are generally applied which correspond to 10 to 1000 mg of pure active ingredient per application.



   Devices suitable for applying the ointment that are available on the market are elongated tube cannulas or tube openings that are inserted into the nostrils. If necessary, the agent can also be applied to the nasal mucosa using a finger or a cotton swab. If necessary, the application can be repeated several times and over a longer period of time without undesirable side effects, as clinical trials in humans have shown.

Claims (8)

PATENTANSPRÜCHE 1. Mittel in Salbenform, insbesondere zur Behandlung von allergischen und vasomotorischen Rhinitiden, dadurch gekennzeichnet, dass es mindestens eine Steroidverbindung der 16-Methylpregna-1,4-dien-3,20-dion-Reihe und eine Salbengrundlage, welche zur Hauptsache aus einer bei Körpertemperatur flüssigen oder halbflüssigen, die Oberflächenspannung herabsetzenden, physiologisch annehmbaren Komponente besteht, enthält.     PATENT CLAIMS 1. Agent in ointment form, in particular for the treatment of allergic and vasomotor rhinitis, characterized in that there is at least one steroid compound of the 16-methylpregna-1,4-diene-3,20-dione series and an ointment base, which mainly consists of a contains at body temperature liquid or semi-liquid, the surface tension-reducing, physiologically acceptable component. 2. Mittel nach Patentanspruch 1, dadurch gekennzeichnet, dass die Salbengrundlage zur Hauptsache aus Polyalkylenglykolen besteht.  2. Composition according to claim 1, characterized in that the ointment base consists mainly of polyalkylene glycols. 3. Mittel nach Patentanspruch 1 oder 2, dadurch gekennzeichnet, dass die Polyalkylenglykole aus einem Gemisch von Polyäthylenglykolen von verschiedenem Molekulargewicht bestehen.  3. Composition according to claim 1 or 2, characterized in that the polyalkylene glycols consist of a mixture of polyethylene glycols of different molecular weights. 4. Mittel nach einem der Patentansprüche 1 bis 3, dadurch gekennzeichnet, dass die Salbengrundlage ausserdem mindestens einen höheren Fettalkohol wie z.B. Cetylalkohol und/oder Stearylalkohol enthält.  4. Agent according to one of claims 1 to 3, characterized in that the ointment base is also at least one higher fatty alcohol such as Contains cetyl alcohol and / or stearyl alcohol. 5. Mittel nach einem der Patentansprüche 1 bis 4, dadurch gekennzeichnet, dass es ausserdem ein Konservierungsmittel enthält, z.B. ein Salz- oder einen Ester der Benzoesäure.  5. Agent according to one of claims 1 to 4, characterized in that it also contains a preservative, e.g. a salt or an ester of benzoic acid. 6. Mittel nach einem der Patentansprüche 1 bis 5, dadurch gekennzeichnet, dass es ausserdem Natriumchlorid, vorzugsweise in Form von Meersalz, enthält.  6. Composition according to one of claims 1 to 5, characterized in that it also contains sodium chloride, preferably in the form of sea salt. 7. Mittel nach einem der Patentansprüche 1 bis 6, dadurch gekennzeichnet, dass es als Wirkstoff 9-Fluor 1113, 17,21-trihydroxy-16z-methylpregna- 1 ,4-dien-3,20-dion oder einen Ester davon, z.B. das tert.-Butylacetat, enthält.  7. Composition according to one of the claims 1 to 6, characterized in that it contains 9-fluorine 1113, 17,21-trihydroxy-16z-methylpregna-1,4-diene-3,20-dione or an ester thereof, e.g. contains the tert-butyl acetate. 8. Mittel nach einem der Patentansprüche 1 bis 6, dadurch gekennzeichnet, dass es als Wirkstoff 9-Chlor -11 1 7,21-trihydroxy- 1 613-methylpregna-l ,4-dien-3,20-dion oder dessen Ester, z.B. das 21-Acetat oder das Dipropionat, enthält.  8. Composition according to one of the claims 1 to 6, characterized in that it contains 9-chloro -11 1 7,21-trihydroxy-1,613-methylpregna-l, 4-diene-3,20-dione or its ester as active ingredient, e.g. 21-acetate or dipropionate. BESCHREIBUNG  DESCRIPTION Die Erfindung betrifft ein Mittel in Salbenform, insbesondere zur Behandlung von allergischen und vasomotorischen Rhinitiden, dessen wesentliche Bestandteile ein oder mehrere Wirkstoffe der 16-Methylpregna-1,4-dien-3,20dion-Reihe sowie eine Salbengrundlage auf der Basis von bei Körpertemperatur flüssigen oder halbflüssigen, die Oberflächenspannung herabsetzenden Verbindungen sind.  The invention relates to an agent in ointment form, in particular for the treatment of allergic and vasomotor rhinitis, the essential components of which are one or more active ingredients of the 16-methylpregna-1,4-diene-3,20dione series and an ointment base on the basis of those which are liquid at body temperature or semi-fluid compounds that reduce surface tension. Die als Wirkstoffe verwendeten Corticosteroide üben eine ausgezeichnete antiallergische Wirkung auf die Nasenschleimhäute aus. Bisher wurden sie zu diesem Zweck als Nasensprays eingesetzt, wobei sie aber eine sehr unangenehme und unerwünschte Austrocknung der Schleimhäute hervorriefen.  The corticosteroids used as active substances have an excellent anti-allergic effect on the nasal mucosa. So far, they have been used for this purpose as nasal sprays, but they have caused a very unpleasant and undesirable drying of the mucous membranes. Aufgabe der Erfindung war es daher, ein Mittel zu entwickeln, welches die positiven Wirkungen der Corticosteroide ohne das Austrocknen der Nasenschleimhäute erzielt.  The object of the invention was therefore to develop an agent which achieves the positive effects of corticosteroids without drying out the nasal mucous membranes. Das erfindungsgemässe Mittel ist in Patentanspruch 1 definiert.  The agent according to the invention is defined in claim 1. Das erfindungsgemässe Mittel bekämpft mit Hilfe der Corticosteroide insbesondere die unten genannten Krankheitssymptome. Durch die spezielle Salbengrundlage bleibt die Wirkung der Corticosteroide voll erhalten und gleichzeitig bleiben überraschenderweise die Schleimhäute während der Entfaltung der Wirkung feucht. Die austrocknende Nebenwirkung der Corticosteroide wird durch die befeuchtende Wirkung der Salbengrundlage aufgehoben. Dadurch bleiben die physiologischen Zustände der Schleimhäute erhalten, was mit wässerigen Präparaten nicht immer der Fall ist.  With the help of corticosteroids, the agent according to the invention in particular combats the disease symptoms mentioned below. Due to the special ointment base, the effect of the corticosteroids is fully preserved and, at the same time, surprisingly the mucous membranes remain moist during the development of the effect. The drying side effect of the corticosteroids is eliminated by the moisturizing effect of the ointment base. As a result, the physiological conditions of the mucous membranes are preserved, which is not always the case with aqueous preparations. Als Hauptbestandteil der Salbengrundlage dient eine bei Körpertemperatur flüssige oder halbflüssige die Oberflächenspannung herabsetzende Komponenente, die selbstverständlich physiologisch annehmbar sein muss. Verbindungen dieser Art, die allein oder im Gemisch verwendet werden können, sind z. B. Polyalkylenglykole, insbesondere Poly äthylenglykole. Eine besonders bevorzugte Komponente besteht aus einem Gemisch von Polyäthylenglykolen von verschiedenem Molekulargewicht, z.B. Polyäthylenglykol 600, Polyäthylenglykol 1000, Polyäthylenglykol 2000, Polyäthylenglykol 3000 und Polyäthylenglykol 5000, die in verschiedenen Gemischen von zwei oder mehr Komponenten und in verschiedenen Mengenverhältnissen miteinander vermischt werden können.  The main component of the ointment base is a component which is liquid or semi-liquid at body temperature and which reduces the surface tension, which of course must be physiologically acceptable. Compounds of this type, which can be used alone or in a mixture, are e.g. B. polyalkylene glycols, especially poly ethylene glycols. A particularly preferred component consists of a mixture of polyethylene glycols of different molecular weights, e.g. Polyethylene glycol 600, polyethylene glycol 1000, polyethylene glycol 2000, polyethylene glycol 3000 and polyethylene glycol 5000, which can be mixed in different mixtures of two or more components and in different proportions. Es hat sich ferner als vorteilhaft erwiesen, der Salbe weitere, für Nasensalben bekannte Zusätze beizufügen, z.B.  It has also proven advantageous to add further additives known to nasal ointments to the ointment, e.g. Verbindungen mit einer gewissen Schmierwirkung, wie höhere Fettalkohole; Kochsalz, insbesondere in Form von Meersalz, sowie Konservierungsmittel, z. B. Benzoesäuresalze oder -ester. Compounds with a certain lubricating effect, such as higher fatty alcohols; Cooking salt, especially in the form of sea salt, and preservatives, e.g. B. benzoic acid salts or esters. Als Wirkstoffe eignen sich bekannte Verbindungen der 16-Methyl-pregna-1,4-dien-3,20-dion-Reihe wie Dexamethason und Beclomethason und deren Derivate, insbesondere deren Ester.  Known compounds of the 16-methyl-pregna-1,4-diene-3,20-dione series, such as dexamethasone and beclomethasone and their derivatives, in particular their esters, are suitable as active ingredients. Geeignete Wirkstoffkonzentrationen liegen im allgemeinen bei etwa 0,1 - 2 Gew.%.  Suitable drug concentrations are generally around 0.1-2% by weight. Patienten, welche auf Pollen oder andere Substanzen allergisch reagieren, leiden jährlich und in ständig steigendem Masse an den Folgen dieser Allergien mit Nasentropfen, tränenden und geschwollenen Augen, etc. In extremen Fällen sind diese Patienten so stark behindert, dass Arbeitsunfähigkeit auftritt. Viele dieser Patienten werden mit Medikamenten behandelt, die als unerwünschte Nebenwirkung die Schleimhäute austrocknen lassen. Dies wird durch das erfindungsgemässe Mittel verhindert. Eine weitere Patientengruppe leidet an vasomotorischen Rhinitiden, deren Symptome den allergischen Rhinitiden ähnelt.  Patients who are allergic to pollen or other substances suffer annually and to an ever increasing extent from the consequences of these allergies with nose drops, watery and swollen eyes, etc. In extreme cases, these patients are so severely handicapped that they are unable to work. Many of these patients are treated with medications that cause the mucous membranes to dry out as an undesirable side effect. This is prevented by the agent according to the invention. Another group of patients suffers from vasomotor rhinitis, the symptoms of which are similar to allergic rhinitis. Es besteht daher auch hier die Notwendigkeit, diese unangenehmen Symptome mit einem geeigneten Mittel zu behandeln, dessen Nebenwirkungen auf ein Minimum reduziert sind, was mit dem erfindungsgemässen Mittel auf einfache Weise ermöglicht wird. Durch die spezielle Salbengrundlage, z.B. auf Polyalkylenglykol-Basis, werden die Nebenwirkungen der Wirkstoffe aufgehoben und eine optimale Behandlung ist gewährleistet.  There is therefore also a need to treat these unpleasant symptoms with a suitable agent, the side effects of which are reduced to a minimum, which is made possible in a simple manner with the agent according to the invention. Due to the special ointment base, e.g. based on polyalkylene glycol, the side effects of the active ingredients are eliminated and optimal treatment is guaranteed.   Mit Hilfe dieses erfindungsgemässen Mittels wird die Austrocknung der Nasenschleimhäute erfolgreich verhindert und Erkrankungen, wie z. B. Rhinitis allergica und vasomotorica, können innert kurzer Zeit erfolgreich behandelt werden, so dass nach wenigen Minuten schon subjektiv und objektiv eine wesentliche Besserung des Zustandes des Patienten festgestellt werden kann.  With the help of this agent the drying of the nasal mucous membranes is successfully prevented and diseases such as. B. Rhinitis allergica and vasomotorica, can be treated successfully within a short time, so that after a few minutes a substantial improvement in the patient's condition can be determined subjectively and objectively. Nachstehend wird die Erfindung durch zwei Beispiele näher erläutert.  The invention is explained in more detail below by means of two examples. Beispiel 1 Aus den folgenden Bestandteilen wurde auf übliche Weise eine Nasensalbe hergestellt: Polyäthylenglykol 600 40 g Polyäthylenglykol 2000 20 g Cetylalkohol 10 g Sorbitol 5g Meersalz (NaCl + Spurenelemente) 1,3 g Methylparabenzoat 0,1 g **WARNUNG** Ende CLMS Feld konnte Anfang DESC uberlappen**.  example 1 A nasal ointment was prepared in the usual way from the following constituents: polyethylene glycol 600 40 g polyethylene glycol 2000 20 g cetyl alcohol 10 g sorbitol 5 g sea salt (NaCl + trace elements) 1.3 g methyl parabenzoate 0.1 g ** WARNING ** End of CLMS field could overlap beginning of DESC **.
CH231686A 1986-06-09 1986-06-09 Corticosteroid ointment compsns. - comprise e.g. dexamethasone in poly:alkylene glycol base, and are used esp. for treating rhinitis CH668188A5 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CH231686A CH668188A5 (en) 1986-06-09 1986-06-09 Corticosteroid ointment compsns. - comprise e.g. dexamethasone in poly:alkylene glycol base, and are used esp. for treating rhinitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH231686A CH668188A5 (en) 1986-06-09 1986-06-09 Corticosteroid ointment compsns. - comprise e.g. dexamethasone in poly:alkylene glycol base, and are used esp. for treating rhinitis

Publications (1)

Publication Number Publication Date
CH668188A5 true CH668188A5 (en) 1988-12-15

Family

ID=4230954

Family Applications (1)

Application Number Title Priority Date Filing Date
CH231686A CH668188A5 (en) 1986-06-09 1986-06-09 Corticosteroid ointment compsns. - comprise e.g. dexamethasone in poly:alkylene glycol base, and are used esp. for treating rhinitis

Country Status (1)

Country Link
CH (1) CH668188A5 (en)

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002062269A1 (en) * 2001-02-06 2002-08-15 Goepferich Achim Spacing device for releasing active substances in the paranasal sinus
US7559925B2 (en) 2006-09-15 2009-07-14 Acclarent Inc. Methods and devices for facilitating visualization in a surgical environment
US7645272B2 (en) 2004-04-21 2010-01-12 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US7654997B2 (en) 2004-04-21 2010-02-02 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitus and other disorders of the ears, nose and/or throat
US7720521B2 (en) 2004-04-21 2010-05-18 Acclarent, Inc. Methods and devices for performing procedures within the ear, nose, throat and paranasal sinuses
US7771409B2 (en) 2004-04-21 2010-08-10 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US8080000B2 (en) 2004-04-21 2011-12-20 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US8100933B2 (en) 2002-09-30 2012-01-24 Acclarent, Inc. Method for treating obstructed paranasal frontal sinuses
US8114062B2 (en) 2004-04-21 2012-02-14 Acclarent, Inc. Devices and methods for delivering therapeutic substances for the treatment of sinusitis and other disorders
US8114113B2 (en) 2005-09-23 2012-02-14 Acclarent, Inc. Multi-conduit balloon catheter
US8118757B2 (en) 2007-04-30 2012-02-21 Acclarent, Inc. Methods and devices for ostium measurement
US8146400B2 (en) 2004-04-21 2012-04-03 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US8172828B2 (en) 2004-04-21 2012-05-08 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures
US8182432B2 (en) 2008-03-10 2012-05-22 Acclarent, Inc. Corewire design and construction for medical devices
US8190389B2 (en) 2006-05-17 2012-05-29 Acclarent, Inc. Adapter for attaching electromagnetic image guidance components to a medical device
US8388642B2 (en) 2005-01-18 2013-03-05 Acclarent, Inc. Implantable devices and methods for treating sinusitis and other disorders
US8414473B2 (en) 2004-04-21 2013-04-09 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US8435290B2 (en) 2009-03-31 2013-05-07 Acclarent, Inc. System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx
US8439687B1 (en) 2006-12-29 2013-05-14 Acclarent, Inc. Apparatus and method for simulated insertion and positioning of guidewares and other interventional devices
US8485199B2 (en) 2007-05-08 2013-07-16 Acclarent, Inc. Methods and devices for protecting nasal turbinate during surgery
US8702626B1 (en) 2004-04-21 2014-04-22 Acclarent, Inc. Guidewires for performing image guided procedures
US8747389B2 (en) 2004-04-21 2014-06-10 Acclarent, Inc. Systems for treating disorders of the ear, nose and throat
US8764729B2 (en) 2004-04-21 2014-07-01 Acclarent, Inc. Frontal sinus spacer
US8864787B2 (en) 2004-04-21 2014-10-21 Acclarent, Inc. Ethmoidotomy system and implantable spacer devices having therapeutic substance delivery capability for treatment of paranasal sinusitis
US8894614B2 (en) 2004-04-21 2014-11-25 Acclarent, Inc. Devices, systems and methods useable for treating frontal sinusitis
US8932276B1 (en) 2004-04-21 2015-01-13 Acclarent, Inc. Shapeable guide catheters and related methods
US8951225B2 (en) 2005-06-10 2015-02-10 Acclarent, Inc. Catheters with non-removable guide members useable for treatment of sinusitis
US8979888B2 (en) 2008-07-30 2015-03-17 Acclarent, Inc. Paranasal ostium finder devices and methods
US9039680B2 (en) 2004-08-04 2015-05-26 Acclarent, Inc. Implantable devices and methods for delivering drugs and other substances to treat sinusitis and other disorders
US9072626B2 (en) 2009-03-31 2015-07-07 Acclarent, Inc. System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx
US9089258B2 (en) 2004-04-21 2015-07-28 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US9101384B2 (en) 2004-04-21 2015-08-11 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, Nose and/or throat
US9155492B2 (en) 2010-09-24 2015-10-13 Acclarent, Inc. Sinus illumination lightwire device
US9265407B2 (en) 2004-04-21 2016-02-23 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US9351750B2 (en) 2004-04-21 2016-05-31 Acclarent, Inc. Devices and methods for treating maxillary sinus disease
US9399121B2 (en) 2004-04-21 2016-07-26 Acclarent, Inc. Systems and methods for transnasal dilation of passageways in the ear, nose or throat
US9433437B2 (en) 2013-03-15 2016-09-06 Acclarent, Inc. Apparatus and method for treatment of ethmoid sinusitis
US9468362B2 (en) 2004-04-21 2016-10-18 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US9629684B2 (en) 2013-03-15 2017-04-25 Acclarent, Inc. Apparatus and method for treatment of ethmoid sinusitis
US9820688B2 (en) 2006-09-15 2017-11-21 Acclarent, Inc. Sinus illumination lightwire device
US10188413B1 (en) 2004-04-21 2019-01-29 Acclarent, Inc. Deflectable guide catheters and related methods
US10206821B2 (en) 2007-12-20 2019-02-19 Acclarent, Inc. Eustachian tube dilation balloon with ventilation path
US10349971B2 (en) 2011-06-29 2019-07-16 CARDINAL HEALTH SWITZERLAND 515 GmbH System and method for dilating and adjusting flexibility in a guiding device
US10524814B2 (en) 2009-03-20 2020-01-07 Acclarent, Inc. Guide system with suction
US11065061B2 (en) 2004-04-21 2021-07-20 Acclarent, Inc. Systems and methods for performing image guided procedures within the ear, nose, throat and paranasal sinuses
US11529502B2 (en) 2004-04-21 2022-12-20 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures
US11957318B2 (en) 2021-04-29 2024-04-16 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat

Cited By (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002062269A1 (en) * 2001-02-06 2002-08-15 Goepferich Achim Spacing device for releasing active substances in the paranasal sinus
US8740929B2 (en) 2001-02-06 2014-06-03 Acclarent, Inc. Spacing device for releasing active substances in the paranasal sinus
US8100933B2 (en) 2002-09-30 2012-01-24 Acclarent, Inc. Method for treating obstructed paranasal frontal sinuses
US9457175B2 (en) 2002-09-30 2016-10-04 Acclarent, Inc. Balloon catheters and methods for treating paranasal sinuses
US8764786B2 (en) 2002-09-30 2014-07-01 Acclarent, Inc. Balloon catheters and methods for treating paranasal sinuses
US8317816B2 (en) 2002-09-30 2012-11-27 Acclarent, Inc. Balloon catheters and methods for treating paranasal sinuses
US8932276B1 (en) 2004-04-21 2015-01-13 Acclarent, Inc. Shapeable guide catheters and related methods
US8777926B2 (en) 2004-04-21 2014-07-15 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasel or paranasal structures
US8088101B2 (en) 2004-04-21 2012-01-03 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US8090433B2 (en) 2004-04-21 2012-01-03 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US7803150B2 (en) 2004-04-21 2010-09-28 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US8961495B2 (en) 2004-04-21 2015-02-24 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US10034682B2 (en) 2004-04-21 2018-07-31 Acclarent, Inc. Devices, systems and methods useable for treating frontal sinusitis
US11589742B2 (en) 2004-04-21 2023-02-28 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US8123722B2 (en) 2004-04-21 2012-02-28 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US8142422B2 (en) 2004-04-21 2012-03-27 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, nose and/or throat
US8146400B2 (en) 2004-04-21 2012-04-03 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US8172828B2 (en) 2004-04-21 2012-05-08 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures
US11529502B2 (en) 2004-04-21 2022-12-20 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures
US11511090B2 (en) 2004-04-21 2022-11-29 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US7771409B2 (en) 2004-04-21 2010-08-10 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US9826999B2 (en) 2004-04-21 2017-11-28 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US8414473B2 (en) 2004-04-21 2013-04-09 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US8425457B2 (en) 2004-04-21 2013-04-23 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitus and other disorder of the ears, nose and/or throat
US11202644B2 (en) 2004-04-21 2021-12-21 Acclarent, Inc. Shapeable guide catheters and related methods
US11065061B2 (en) 2004-04-21 2021-07-20 Acclarent, Inc. Systems and methods for performing image guided procedures within the ear, nose, throat and paranasal sinuses
US11020136B2 (en) 2004-04-21 2021-06-01 Acclarent, Inc. Deflectable guide catheters and related methods
US8702626B1 (en) 2004-04-21 2014-04-22 Acclarent, Inc. Guidewires for performing image guided procedures
US8715169B2 (en) 2004-04-21 2014-05-06 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US8721591B2 (en) 2004-04-21 2014-05-13 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures
US7720521B2 (en) 2004-04-21 2010-05-18 Acclarent, Inc. Methods and devices for performing procedures within the ear, nose, throat and paranasal sinuses
US8747389B2 (en) 2004-04-21 2014-06-10 Acclarent, Inc. Systems for treating disorders of the ear, nose and throat
US8764709B2 (en) 2004-04-21 2014-07-01 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US8764726B2 (en) 2004-04-21 2014-07-01 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US8764729B2 (en) 2004-04-21 2014-07-01 Acclarent, Inc. Frontal sinus spacer
US7654997B2 (en) 2004-04-21 2010-02-02 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitus and other disorders of the ears, nose and/or throat
US8961398B2 (en) 2004-04-21 2015-02-24 Acclarent, Inc. Methods and apparatus for treating disorders of the ear, nose and throat
US8828041B2 (en) 2004-04-21 2014-09-09 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US8852143B2 (en) 2004-04-21 2014-10-07 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US8858586B2 (en) 2004-04-21 2014-10-14 Acclarent, Inc. Methods for enlarging ostia of paranasal sinuses
US8864787B2 (en) 2004-04-21 2014-10-21 Acclarent, Inc. Ethmoidotomy system and implantable spacer devices having therapeutic substance delivery capability for treatment of paranasal sinusitis
US8870893B2 (en) 2004-04-21 2014-10-28 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, nose and/or throat
US8894614B2 (en) 2004-04-21 2014-11-25 Acclarent, Inc. Devices, systems and methods useable for treating frontal sinusitis
US8905922B2 (en) 2004-04-21 2014-12-09 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, nose and/or throat
US10098652B2 (en) 2004-04-21 2018-10-16 Acclarent, Inc. Systems and methods for transnasal dilation of passageways in the ear, nose or throat
US8945088B2 (en) 2004-04-21 2015-02-03 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures
US7645272B2 (en) 2004-04-21 2010-01-12 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US8080000B2 (en) 2004-04-21 2011-12-20 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US8114062B2 (en) 2004-04-21 2012-02-14 Acclarent, Inc. Devices and methods for delivering therapeutic substances for the treatment of sinusitis and other disorders
US10188413B1 (en) 2004-04-21 2019-01-29 Acclarent, Inc. Deflectable guide catheters and related methods
US11019989B2 (en) 2004-04-21 2021-06-01 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US10441758B2 (en) 2004-04-21 2019-10-15 Acclarent, Inc. Frontal sinus spacer
US9649477B2 (en) 2004-04-21 2017-05-16 Acclarent, Inc. Frontal sinus spacer
US9055965B2 (en) 2004-04-21 2015-06-16 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US10874838B2 (en) 2004-04-21 2020-12-29 Acclarent, Inc. Systems and methods for transnasal dilation of passageways in the ear, nose or throat
US10492810B2 (en) 2004-04-21 2019-12-03 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, nose and/or throat
US9089258B2 (en) 2004-04-21 2015-07-28 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US9101384B2 (en) 2004-04-21 2015-08-11 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, Nose and/or throat
US9107574B2 (en) 2004-04-21 2015-08-18 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US10856727B2 (en) 2004-04-21 2020-12-08 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US9167961B2 (en) 2004-04-21 2015-10-27 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US10500380B2 (en) 2004-04-21 2019-12-10 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US10631756B2 (en) 2004-04-21 2020-04-28 Acclarent, Inc. Guidewires for performing image guided procedures
US9220879B2 (en) 2004-04-21 2015-12-29 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US9241834B2 (en) 2004-04-21 2016-01-26 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US9265407B2 (en) 2004-04-21 2016-02-23 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US9610428B2 (en) 2004-04-21 2017-04-04 Acclarent, Inc. Devices, systems and methods useable for treating frontal sinusitis
US9351750B2 (en) 2004-04-21 2016-05-31 Acclarent, Inc. Devices and methods for treating maxillary sinus disease
US9370649B2 (en) 2004-04-21 2016-06-21 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US9399121B2 (en) 2004-04-21 2016-07-26 Acclarent, Inc. Systems and methods for transnasal dilation of passageways in the ear, nose or throat
US10806477B2 (en) 2004-04-21 2020-10-20 Acclarent, Inc. Systems and methods for transnasal dilation of passageways in the ear, nose or throat
US11864725B2 (en) 2004-04-21 2024-01-09 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, nose and/or throat
US10779752B2 (en) 2004-04-21 2020-09-22 Acclarent, Inc. Guidewires for performing image guided procedures
US9468362B2 (en) 2004-04-21 2016-10-18 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US9554691B2 (en) 2004-04-21 2017-01-31 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US10702295B2 (en) 2004-04-21 2020-07-07 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US10695080B2 (en) 2004-04-21 2020-06-30 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, nose and/or throat
US9084876B2 (en) 2004-08-04 2015-07-21 Acclarent, Inc. Implantable devices and methods for delivering drugs and other substances to treat sinusitis and other disorders
US9039657B2 (en) 2004-08-04 2015-05-26 Acclarent, Inc. Implantable devices and methods for delivering drugs and other substances to treat sinusitis and other disorders
US9039680B2 (en) 2004-08-04 2015-05-26 Acclarent, Inc. Implantable devices and methods for delivering drugs and other substances to treat sinusitis and other disorders
US9308361B2 (en) 2005-01-18 2016-04-12 Acclarent, Inc. Implantable devices and methods for treating sinusitis and other disorders
US8388642B2 (en) 2005-01-18 2013-03-05 Acclarent, Inc. Implantable devices and methods for treating sinusitis and other disorders
US8951225B2 (en) 2005-06-10 2015-02-10 Acclarent, Inc. Catheters with non-removable guide members useable for treatment of sinusitis
US10842978B2 (en) 2005-06-10 2020-11-24 Acclarent, Inc. Catheters with non-removable guide members useable for treatment of sinusitis
US10124154B2 (en) 2005-06-10 2018-11-13 Acclarent, Inc. Catheters with non-removable guide members useable for treatment of sinusitis
US10639457B2 (en) 2005-09-23 2020-05-05 Acclarent, Inc. Multi-conduit balloon catheter
US8968269B2 (en) 2005-09-23 2015-03-03 Acclarent, Inc. Multi-conduit balloon catheter
US9999752B2 (en) 2005-09-23 2018-06-19 Acclarent, Inc. Multi-conduit balloon catheter
US8114113B2 (en) 2005-09-23 2012-02-14 Acclarent, Inc. Multi-conduit balloon catheter
US9198736B2 (en) 2006-05-17 2015-12-01 Acclarent, Inc. Adapter for attaching electromagnetic image guidance components to a medical device
US8190389B2 (en) 2006-05-17 2012-05-29 Acclarent, Inc. Adapter for attaching electromagnetic image guidance components to a medical device
US9629656B2 (en) 2006-05-17 2017-04-25 Acclarent, Inc. Adapter for attaching electromagnetic image guidance components to a medical device
US9572480B2 (en) 2006-09-15 2017-02-21 Acclarent, Inc. Methods and devices for facilitating visualization in a surgical environment
US7559925B2 (en) 2006-09-15 2009-07-14 Acclarent Inc. Methods and devices for facilitating visualization in a surgical environment
US9179823B2 (en) 2006-09-15 2015-11-10 Acclarent, Inc. Methods and devices for facilitating visualization in a surgical environment
US10716629B2 (en) 2006-09-15 2020-07-21 Acclarent, Inc. Methods and devices for facilitating visualization in a surgical environment
US9603506B2 (en) 2006-09-15 2017-03-28 Acclarent, Inc. Methods and devices for facilitating visualization in a surgical environment
US9820688B2 (en) 2006-09-15 2017-11-21 Acclarent, Inc. Sinus illumination lightwire device
US8439687B1 (en) 2006-12-29 2013-05-14 Acclarent, Inc. Apparatus and method for simulated insertion and positioning of guidewares and other interventional devices
US8118757B2 (en) 2007-04-30 2012-02-21 Acclarent, Inc. Methods and devices for ostium measurement
US9615775B2 (en) 2007-04-30 2017-04-11 Acclarent, Inc. Methods and devices for ostium measurements
US9463068B2 (en) 2007-05-08 2016-10-11 Acclarent, Inc. Methods and devices for protecting nasal turbinates
US8485199B2 (en) 2007-05-08 2013-07-16 Acclarent, Inc. Methods and devices for protecting nasal turbinate during surgery
US11850120B2 (en) 2007-12-20 2023-12-26 Acclarent, Inc. Eustachian tube dilation balloon with ventilation path
US11311419B2 (en) 2007-12-20 2022-04-26 Acclarent, Inc. Eustachian tube dilation balloon with ventilation path
US10206821B2 (en) 2007-12-20 2019-02-19 Acclarent, Inc. Eustachian tube dilation balloon with ventilation path
US9861793B2 (en) 2008-03-10 2018-01-09 Acclarent, Inc. Corewire design and construction for medical devices
US8182432B2 (en) 2008-03-10 2012-05-22 Acclarent, Inc. Corewire design and construction for medical devices
US11116392B2 (en) 2008-07-30 2021-09-14 Acclarent, Inc. Paranasal ostium finder devices and methods
US10271719B2 (en) 2008-07-30 2019-04-30 Acclarent, Inc. Paranasal ostium finder devices and methods
US8979888B2 (en) 2008-07-30 2015-03-17 Acclarent, Inc. Paranasal ostium finder devices and methods
US9750401B2 (en) 2008-07-30 2017-09-05 Acclarent, Inc. Paranasal ostium finder devices and methods
US11207087B2 (en) 2009-03-20 2021-12-28 Acclarent, Inc. Guide system with suction
US10524814B2 (en) 2009-03-20 2020-01-07 Acclarent, Inc. Guide system with suction
US9636258B2 (en) 2009-03-31 2017-05-02 Acclarent, Inc. System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx
US8435290B2 (en) 2009-03-31 2013-05-07 Acclarent, Inc. System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx
US10376416B2 (en) 2009-03-31 2019-08-13 Acclarent, Inc. System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx
US9072626B2 (en) 2009-03-31 2015-07-07 Acclarent, Inc. System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx
US9155492B2 (en) 2010-09-24 2015-10-13 Acclarent, Inc. Sinus illumination lightwire device
US10349971B2 (en) 2011-06-29 2019-07-16 CARDINAL HEALTH SWITZERLAND 515 GmbH System and method for dilating and adjusting flexibility in a guiding device
US10524869B2 (en) 2013-03-15 2020-01-07 Acclarent, Inc. Apparatus and method for treatment of ethmoid sinusitis
US9629684B2 (en) 2013-03-15 2017-04-25 Acclarent, Inc. Apparatus and method for treatment of ethmoid sinusitis
US9433437B2 (en) 2013-03-15 2016-09-06 Acclarent, Inc. Apparatus and method for treatment of ethmoid sinusitis
US11957318B2 (en) 2021-04-29 2024-04-16 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat

Similar Documents

Publication Publication Date Title
CH668188A5 (en) Corticosteroid ointment compsns. - comprise e.g. dexamethasone in poly:alkylene glycol base, and are used esp. for treating rhinitis
DE69535607T2 (en) Composition containing nitrogen oxide donors and method for the treatment of anal diseases
EP0053754B1 (en) Drug for antagonizing snore, and method for its application
DE69938390T2 (en) USE OF A COMPOSITION CONTAINING FORMOTEROL AND BUDESONIDES TO PREVENT OR TREAT AN ACUTE ASTM STATE
DE2448871A1 (en) STABILIZED TRANS-RETINIC ACID CREAM
DE2046119A1 (en) Middle) to treat acne
DE2818553A1 (en) COMPOSITION FOR THE TREATMENT OF PROLIFERATIVE SKIN DISEASES
DD298352A5 (en) TRETINOINE CONTAINING PREPARATION AND METHOD FOR THE PRODUCTION THEREOF
DE3411225C2 (en)
EP0765663A2 (en) Use of dienogest for the manufacture of a medicament for the treatment of the skin by topical application
DE20318634U1 (en) Topical compositions for preventing or treating rhinitis, comprising sympathomimetic agent with vasoconstrictive and/or mucosal swelling reducing action and glycosaminoglycan to reduce side-effects
DE3317530A1 (en) Antisnoring composition
DE1804801C3 (en) Acne treatment agents
DE102008036725B4 (en) Pharmaceutical composition for nasal application
DE3317692A1 (en) USE OF METKEPHAMIDE OR A PHARMACEUTICALLY SAFE SALT THEREOF AS AN ANALGETIC IN SUBSTANTIVE FEMALE ANIMALS AND ESPECIALLY IN PREGNANT WOMEN
DE3724691C2 (en) Pharmaceutical agent for the local therapy of flaking skin diseases
DE69634472T2 (en) Adrenal corticosteroid-containing therapeutic composition for external use for dermatitis treatment
DE3146570C2 (en)
DE3443242A1 (en) Glycyrrhizin and a medicament containing an active compound
DE2912438C2 (en)
DE3941263C1 (en)
CH684520A5 (en) A composition for accelerating the healing of wounds.
DE19541815B4 (en) Use of a solution of polyethylene glycol in water as an aqueous rinse solution for the prevention or treatment of viscous mucus associated with radiation and / or chemotherapy-induced mucosal disorders
DE69838809T2 (en) USE OF 17A-ESTRADIOL FOR THE TREATMENT OF SKIN AGING OR SUNSHIELD SKIN AND / OR SKIN ATROPHY
DE2243320C2 (en) Medicines based on compounds containing iodine and anti-inflammatory corticosteroids

Legal Events

Date Code Title Description
PL Patent ceased